About Amber Therapeutics
Amber Therapeutics is a company based in London (United Kingdom) founded in 2021 by Tim Denison and Aidan Crawley.. Amber Therapeutics has raised $100 million across 2 funding rounds from investors including Intuitive, UK Research and Innovation and Oxford Science Enterprises. Amber Therapeutics has completed 1 acquisition, including Bioinduction. Amber Therapeutics offers products and services including Picostim System and Amber-UI Therapy. Amber Therapeutics operates in a competitive market with competitors including Axonics, NeuSpera Medical, UroMems, American Medical Systems and Levee Medical, among others.
- Headquarter London, United Kingdom
- Founders Tim Denison, Aidan Crawley
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$100 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series A
Jun 09, 2024
-
Investors
Intuitive
& 6 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amber Therapeutics
Amber Therapeutics offers a comprehensive portfolio of products and services, including Picostim System and Amber-UI Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides adaptive neuromodulation for treating mixed urinary incontinence.
Addresses urge and stress incontinence through closed-loop bioelectrical stimulation.
Unlock access to complete
Unlock access to complete
Funding Insights of Amber Therapeutics
Amber Therapeutics has successfully raised a total of $100M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $100 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $100.0M
- First Round First Round
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2024 | Amount | Series A - Amber Therapeutics | Valuation | New Enterprise Associates | |
| Jan, 2023 | Amount | Seed - Amber Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Amber Therapeutics
Amber Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Intuitive, UK Research and Innovation and Oxford Science Enterprises. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services for science ventures are provided in Oxford.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in technology, life sciences, and related sectors.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Amber Therapeutics
Amber Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Bioinduction. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Implanted neuromodulation devices for chronic pain are developed and marketed.
|
2002 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Amber Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Amber Therapeutics Comparisons
Competitors of Amber Therapeutics
Amber Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Axonics, NeuSpera Medical, UroMems, American Medical Systems and Levee Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Sacral neuromodulation devices are developed for urinary and bowel control.
|
|
| domain | founded_year | HQ Location |
Miniaturized injectable neuromodulation devices are developed for chronic diseases.
|
|
| domain | founded_year | HQ Location |
Developer of active implantable devices for urological incontinence
|
|
| domain | founded_year | HQ Location |
Devices for the treatment of pelvic disorders
|
|
| domain | founded_year | HQ Location |
Urological devices for post-prostatectomy incontinence are developed by Levee Medical.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Amber Therapeutics
Frequently Asked Questions about Amber Therapeutics
When was Amber Therapeutics founded?
Amber Therapeutics was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Where is Amber Therapeutics located?
Amber Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Amber Therapeutics?
Aidan Crawley is the current CEO of Amber Therapeutics. They have also founded this company.
Is Amber Therapeutics a funded company?
Amber Therapeutics is a funded company, having raised a total of $100M across 2 funding rounds to date.
What does Amber Therapeutics do?
Amber Therapeutics was established in 2021 in London, United Kingdom, within the medtech sector. Bioelectrical therapies targeting functional disorders of the peripheral nervous system are developed by the company. Operations center on implantable closed-loop systems, such as Amber-UI, designed for urge and mixed urinary incontinence. Co-founders Tim Denison and Aidan Crawley lead the efforts in this specialized field.
Who are the top competitors of Amber Therapeutics?
Amber Therapeutics's top competitors include Axonics, NeuSpera Medical and UroMems.
What products or services does Amber Therapeutics offer?
Amber Therapeutics offers Picostim System and Amber-UI Therapy.
How many acquisitions has Amber Therapeutics made?
Amber Therapeutics has made 1 acquisition, including Bioinduction.
Who are Amber Therapeutics's investors?
Amber Therapeutics has 7 investors. Key investors include Intuitive, UK Research and Innovation, Oxford Science Enterprises, 8VC, and NEA.